Genzyme Reports Strong Third-Quarter Financial Results (PR Newswire via Yahoo! Finance)
Genzyme Corp. today reported third-quarter revenue of $808.6 million, 14 percent greater than revenue of $708.1 million in the same quarter a year ago. The increase was driven by contributions from most product areas, highlighting the impact of diversification on the company's ability to grow in a consistent and sustainable way.

FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer (PR Newswire via Yahoo! Finance)
Genentech, Inc. announced today that the U.S. Food and Drug Administration has approved Avastin to be used in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non- squamous, non-small cell lung cancer , the most common type of lung cancer.